مورد إلكتروني

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

التفاصيل البيبلوغرافية
العنوان: Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis
المؤلفون: Zhou, Z, Jardine, MJ, Li, Q, Neuen, BL, Cannon, CP, De Zeeuw, D, Edwards, R, Levin, A, Mahaffey, KW, Perkovic, V, Neal, B, Lindley, RI, Guerrero, RAA, Aizenberg, D, Albisu, JP, Alvarisqueta, A, Bartolacci, I, Berli, MA, Bordonava, A, Calella, P, Cantero, MC, Cartasegna, LR, Cercos, E, Coloma, GC, Colombo, H, Commendatore, V, Cuadrado, J, Cuneo, CA, Cusumano, AM, Douthat, WG, Dran, RD, Farias, E, Fernandez, MF, Finkelstein, H, Fragale, G, Fretes, JO, Garcia, NH, Gastaldi, A, Gelersztein, E, Glenny, JA, Gonzalez, JP, Del Carmen Gonzalez Colaso, P, Goycoa, C, Greloni, GC, Guinsburg, A, Hermida, S, Juncos, LI, Klyver, MI, Kraft, F, Krynski, F, Lanchiotti, PV, De La Fuente, RAL, Marchetta, N, Mele, P, Nicolai, S, Novoa, PA, Orio, SI, Otreras, F, Oviedo, A, Raffaele, P, Resk, JH, Rista, L, Papini, NR, Sala, J, Santos, JC, Schiavi, LB, Sessa, H, Casabella, TS, Ulla, MR, Valdez, M, Vallejos, A, Villarino, A, Visco, VE, Wassermann, A, Zaidman, CJ, Cheung, NW, Droste, C, Fraser, I, Johnson, D, Mah, PM, Nicholls, K, Packham, D, Proietto, J, Roberts, A, Roger, S, Tsang, V, Raduan, RA, Da Costa, FAA, Amodeo, C, Turatti, LAA, Bregman, R, Sanches, FCC, Canani, LH, Chacra, AR, Borges, JLC, Vêncio, SAC, Da Silva Franco, RJ, D'Avila, D, De Souza Portes, E, De Souza, P
بيانات النشر: 2021-05-01
نوع الوثيقة: Electronic Resource
مستخلص: BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect
مصطلحات الفهرس: 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1109 Neurosciences, text, Journal Article, Journal Article
URL: http://handle.unsw.edu.au/1959.4/unsworks_76562
https://orcid.org/0000-0001-6543-7113
https://orcid.org/0000-0002-0160-2375
https://orcid.org/0000-0002-4384-8226
https://orcid.org/0000-0001-9276-8380
https://orcid.org/0000-0002-4257-7620
https://orcid.org/0000-0002-0490-7465
https://orcid.org/0000-0001-6543-7113
https://orcid.org/0000-0002-0160-2375
https://orcid.org/0000-0002-4384-8226
https://orcid.org/0000-0001-9276-8380
https://orcid.org/0000-0002-4257-7620
https://orcid.org/0000-0002-0490-7465
Stroke, 52, 5, 1545-1556
الإتاحة: Open access content. Open access content
https://creativecommons.org/licenses/by-nc-nd/4.0
free_to_read
أرقام أخرى: LJ1 oai:unsworks.library.unsw.edu.au:1959.4/unsworks_76562
10.1161/STROKEAHA.120.031623
urn:issn:0039-2499
urn:issn:1524-4628
1259603886
المصدر المساهم: UNIV OF NEW S WALES
From OAIster®, provided by the OCLC Cooperative.
رقم الأكسشن: edsoai.on1259603886
قاعدة البيانات: OAIster